This study is in progress, not accepting new patients
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at Irvine, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- ID
- NCT04927975
- Phase
- Phase 2 Vitiligo Research Study
- Study Type
- Interventional
- Participants
- About 185 people participating
- Last Updated